---
title: "Bilibili drops 3% to one-month low as interactive-content bet draws attention"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296421067.md"
description: "Bilibili slid to a one-month low in Hong Kong trading; no clear catalyst, but interactive-content push draws attention."
datetime: "2026-08-20T01:41:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296421067.md)
  - [en](https://longbridge.com/en/news/296421067.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296421067.md)
generator: "portal-rs"
---

# Bilibili drops 3% to one-month low as interactive-content bet draws attention

Bilibili (9626.HK) **fell 3.3%** during Hong Kong trading to HK$**129.40**.

The stock has been under pressure despite a broadly higher market in Hong Kong on Thursday, with shares touching an intraday low of HK$**129.10** — the weakest level in about a month.

The decline comes with no clear near-term catalyst. Investors are watching Bilibili's foray into interactive content: the company is testing a new platform called Toy, which has already logged more than **8.5 million** interactions. Bilibili joins peers Kuaishou, Xiaohongshu and Douyin in the emerging interactive-content space.

### Related Stocks

- [09626.HK](https://longbridge.com/en/quote/09626.HK.md)

## Related News & Research

- [Bilibili prices unregistered sale of 6,976,760 shares at HK$ 115.38 each](https://longbridge.com/en/news/298298123.md)
- [What’s Next for Bilibili As Tencent Pivots From Shareholder To Creditor?](https://longbridge.com/en/news/298737598.md)
- [Daiwa: BILIBILI-W Issues USD700M CBs; Innovative Structure Eliminates TENCENT Stake Sale Overhang](https://longbridge.com/en/news/298260090.md)
- [J.P. Morgan Sticks to Its Buy Rating for Bilibili, Inc. Class Z (9626)](https://longbridge.com/en/news/298385444.md)
- [What Tencent’s Bilibili bond swap tells us about its AI playbook](https://longbridge.com/en/news/298222233.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**